niacinamide has been researched along with Luft Disease in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we treated mitochondrial myopathy mice with NR." | 1.40 | Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. ( Auranen, M; Auwerx, J; Carroll, CJ; Euro, L; Forsström, S; Khan, NA; Paetau, I; Pasila, L; Pirinen, E; Suomalainen, A; Velagapudi, V, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schaefer, PM | 1 |
| Huang, J | 1 |
| Butic, A | 1 |
| Perry, C | 1 |
| Yardeni, T | 1 |
| Tan, W | 1 |
| Morrow, R | 1 |
| Baur, JA | 1 |
| Wallace, DC | 1 |
| Tong, D | 1 |
| Schiattarella, GG | 1 |
| Jiang, N | 1 |
| Altamirano, F | 1 |
| Szweda, PA | 1 |
| Elnwasany, A | 1 |
| Lee, DI | 1 |
| Yoo, H | 1 |
| Kass, DA | 1 |
| Szweda, LI | 1 |
| Lavandero, S | 1 |
| Verdin, E | 1 |
| Gillette, TG | 1 |
| Hill, JA | 1 |
| Khan, NA | 1 |
| Auranen, M | 1 |
| Paetau, I | 1 |
| Pirinen, E | 1 |
| Euro, L | 1 |
| Forsström, S | 1 |
| Pasila, L | 1 |
| Velagapudi, V | 1 |
| Carroll, CJ | 1 |
| Auwerx, J | 1 |
| Suomalainen, A | 1 |
| Lightowlers, RN | 1 |
| Chrzanowska-Lightowlers, ZM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203] | 15 participants (Actual) | Interventional | 2014-06-01 | Completed | |||
| NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521] | 3 participants (Actual) | Interventional | 2019-02-11 | Completed | |||
| Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990] | Phase 2 | 5 participants (Actual) | Interventional | 2019-11-08 | Terminated (stopped due to Enrollment challenges) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| NIAGEN®) | 7 |
Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks
| Intervention | score on a scale (Median) |
|---|---|
| NIAGEN®) | 2 |
Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks
| Intervention | event (Number) |
|---|---|
| NIAGEN®) | 0 |
"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 3 |
Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 0 |
Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks
| Intervention | ng/ml (Median) |
|---|---|
| NIAGEN®) | 810 |
Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks
| Intervention | mg/M^2 (Number) |
|---|---|
| NIAGEN®) | 200 |
4 other studies available for niacinamide and Luft Disease
| Article | Year |
|---|---|
Nicotinamide riboside alleviates exercise intolerance in ANT1-deficient mice.
Topics: Adenine Nucleotide Translocator 1; Animals; Mice; Mitochondrial Myopathies; Muscle Weakness; NAD; Ni | 2022 |
NAD
Topics: Acetylation; Acyl-CoA Dehydrogenase; Animals; Disease Models, Animal; Down-Regulation; Fatty Acids; | 2021 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Forkhead Box Protein O1; Forkhead Transcription F | 2014 |
Salvaging hope: Is increasing NAD(+) a key to treating mitochondrial myopathy?
Topics: Animals; Male; Mitochondria; Mitochondrial Myopathies; Niacinamide; Pyridinium Compounds; Vitamin B | 2014 |